Document Detail


Comparative effects of three different potent renin inhibitors in primates.
MedLine Citation:
PMID:  8319997     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys. In these monkeys, arterial pressure was measured in the conscious state with a telemetry system. Oral and intravenous maximal effective doses of the three renin inhibitors were compared in parallel groups of monkeys. In additional experiments, remikiren was given on top of either CGP 38560A or enalkiren in the same animals. Finally, the three drugs were compared with the angiotensin converting enzyme inhibitor cilazapril. The effects of the three drugs on the plasma components of the renin-angiotensin system (plasma renin activity, immunoreactive renin, and immunoreactive angiotensin II concentrations) were also measured. Our results show that remikiren was as effective as cilazapril and markedly more effective than CGP 38560A or enalkiren in reducing arterial pressure in our monkey model. Interestingly, these differences in arterial pressure could not be explained by differences of in vitro potency or different biochemical changes of the plasma components of the renin-angiotensin system, because the inhibitors all reduced immunoreactive angiotensin II to similarly low levels. One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and enalkiren is able to inhibit renin in a functionally important extraplasmatic compartment.
Authors:
J P Clozel; W Fischli
Related Documents :
940627 - Hypertension and plasma renin activity in experimentally induced chronic pyelonephritis.
3718027 - Pathogenesis of nonocclusive ischemic colitis.
2963067 - Systemic haemodynamics in renovascular hypertension: changes after revascularization wi...
3128117 - Effect of vasopressin blockade on blood pressure during water deprivation in intact and...
18158357 - Deoxycorticosterone acetate salt hypertension in apolipoprotein e-/- mice results in ac...
16749407 - An open-label, randomized, controlled, 4-week comparative clinical trial of barnidipine...
Publication Detail:
Type:  Comparative Study; In Vitro; Journal Article    
Journal Detail:
Title:  Hypertension     Volume:  22     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:  1993 Jul 
Date Detail:
Created Date:  1993-08-05     Completed Date:  1993-08-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  9-17     Citation Subset:  IM    
Affiliation:
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Angiotensin II / blood
Animals
Blood Pressure / drug effects
Cilazapril / administration & dosage,  pharmacology
Dipeptides / administration & dosage,  pharmacology*
Drug Interactions
Heart Rate / drug effects
Humans
Imidazoles / administration & dosage,  pharmacology*
Injections, Intravenous
Oligopeptides / administration & dosage,  pharmacology*
Renin / antagonists & inhibitors*,  blood
Renin-Angiotensin System / drug effects*
Saimiri
Time Factors
Chemical
Reg. No./Substance:
0/Dipeptides; 0/Imidazoles; 0/Oligopeptides; 11128-99-7/Angiotensin II; 113082-98-7/enalkiren; 122088-76-0/CGP 38560; 135669-48-6/remikiren; 92077-78-6/Cilazapril; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Longitudinal assessment of blood pressures in black and white children.
Next Document:  Resting and ambulatory blood pressure differences in Afro-Caribbeans and Europeans.